Xenetic Biosciences, Inc. (NASDAQ:XBIO) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research note issued to investors on Saturday. The brokerage currently has a $3.00 target price on the stock. Zacks Investment Research‘s price objective points to a potential upside of 19.52% from the company’s current price.

According to Zacks, “Xenetic Biosciences Inc. is a biopharmaceutical company. It develops biologic drugs, oncology therapeutics and vaccinations. The Company’s proprietary drug technology platforms include PolyXen (R) for the development of next generation biologic drugs and OncoHist (R) for the development of oncology drugs focused on orphan indications. Xenetic Biosciences Inc. based in United States. “

Xenetic Biosciences (XBIO) opened at 2.51 on Friday. Xenetic Biosciences has a 1-year low of $2.30 and a 1-year high of $5.75. The firm’s 50-day moving average is $2.59 and its 200 day moving average is $3.33. The stock’s market capitalization is $21.88 million.

Xenetic Biosciences (NASDAQ:XBIO) last posted its quarterly earnings data on Monday, August 14th. The company reported ($0.34) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.21) by ($0.13). Equities analysts anticipate that Xenetic Biosciences will post ($0.89) EPS for the current fiscal year.

TRADEMARK VIOLATION WARNING: “Zacks Investment Research Upgrades Xenetic Biosciences, Inc. (XBIO) to “Buy”” was published by American Banking News and is owned by of American Banking News. If you are accessing this piece on another site, it was illegally copied and republished in violation of U.S. and international trademark & copyright legislation. The correct version of this piece can be read at https://www.americanbankingnews.com/2017/09/16/zacks-investment-research-upgrades-xenetic-biosciences-inc-xbio-to-buy-2.html.

About Xenetic Biosciences

Xenetic Biosciences, Inc is a clinical-stage biopharmaceutical company. The Company is focused on the research and development of certain pharmaceutical products for use in humans that includes the use of the Company’s platform technologies that enables the creation of drug therapies primarily for orphan indications.

Get a free copy of the Zacks research report on Xenetic Biosciences (XBIO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Xenetic Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xenetic Biosciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.